Han weidong

Academic / Other · 5 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Active Not Recruiting	Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells	Phase 1 / Phase 2	2021-04-15
Unknown	Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen Hodgkin Lymphoma	Phase 1 / Phase 2	2019-07-30
Recruiting	Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies Malignancies Multiple	Phase 1 / Phase 2	2016-05-01
Unknown	Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas Lymphomas	—	2013-04-01
Unknown	Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or Solid Tumors, B Cell Lymphoma	Phase 1 / Phase 2	2012-12-01